Key result
Treatment with colchicine twice daily in a 67-year-old male with COVID-19-induced pericarditis resulted in symptom resolution and reduction of pericardial effusion from 1.1 cm to 0.6 cm.
Why the study?
Acute pericarditis due to SARS-CoV-2 might be underdiagnosed, and there is an urgent need for diagnostic and therapeutic strategies to better manage COVID-19 patients and diminish complications.
Does colchicine improve clinical symptoms and pericardial effusion in a patient with COVID-19-associated acute pericarditis?
Case Report (n=1)
No
Does colchicine improve clinical symptoms and pericardial effusion in a patient with COVID-19-associated acute pericarditis?
Colchicine may be an effective and safe therapeutic option for managing acute pericarditis secondary to COVID-19 infection, leading to rapid clinical and echocardiographic improvement.
Answers are grounded in this paper and cite their sources.
May support colchicine in COVID-19 pericarditis; hypothesis-generating case report requiring randomized confirmation.
The pericardium is a fibroelastic sac made up of visceral and parietal layers separated by a (potential) space, the pericardial cavity.The most troublesome complication of acute pericarditis is the development of recurrent episodes of pericardial inflammation, occurring in 15% to 32% of cases. Therapeutic modalities are nonspecific and include non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Here we present a case of a patient presenting with pericarditis due to COVID-19. He was successfully treated with colchicine. To our knowledge acute pericarditis due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) might be an under diagnosed condition in this pandemic. We want to share our findings, given the urgent need for different diagnostic and therapeutic strategies in order to better manage COVID-19 patients, and diminish the SARS-CoV-2 complications.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2022) conducted a case report in Pericarditis due to COVID-19 (n=1). Colchicine was evaluated on Resolution of symptoms and reduction in pericardial effusion size. Treatment with colchicine twice daily in a 67-year-old male with COVID-19-induced pericarditis resulted in symptom resolution and reduction of pericardial effusion from 1.1 cm to 0.6 cm.
Synapse has enriched 10 related papers. Consider them for comparative context: